ArticleCancer reports (Hoboken, N.J.)2026
Improvement in Outcomes of Childhood Acute Myeloid Leukemia Treatment: A Survival Analysis at a Reference University Hospital in Rio de Janeiro, Brazil.
Article in Cancer reports (Hoboken, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundAcute myeloid leukemia (AML) represents 15% to 20% of all pediatric acute leukemias and is responsible for nearly 30% of deaths in this population. While high-income countries report overall survival (OS) rates near 75%, survival in Brazil remains significantly lower, ranging between 30% and 40%.
aimsThe objective of this study is to analyze the probability of OS and event-free survival (EFS) in pediatric patients with AML treated at a Brazilian university hospital, evaluate prognostic factors, and compare outcomes with international data. METHODS AND
resultsThis retrospective study included 51 patients (under 14 years old) diagnosed between 2004 and 2023 and treated with BFM-based protocols. The median age was 4.6 years. Patients with acute promyelocytic leukemia (APL) achieved an OS of 100% and EFS of 90%. For other AML subtypes, the 5-year OS and EFS were 53.7% and 43.7%, respectively. Implementation of improved supportive care (ISC) after 2008-including the opening of a pediatric ICU and better infection management-was a pivotal prognostic factor (p < 0.001). Following ISC implementation, OS increased dramatically from 8.3% to 74.5%, and the early death rate dropped to 5.7%, reaching levels comparable to high-income countries.
conclusionsPediatric AML outcomes in developing regions can achieve international standards when intensive chemotherapy is combined with optimized supportive care. The establishment of specialized pediatric intensive care and advanced management of infectious complications are essential pillars for bridging the survival gap in these populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.